YOLT-203

DRUG4 trials

Sponsors

RenJi Hospital, Guangzhou Women and Children's Medical Center, YolTech Therapeutics Co., Ltd

Conditions

PH1Primary Hyperoxaluria Type 1Type 1 Primary Hyperoxaluria

Early Phase 1

Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)

RecruitingNCT06511349

RenJi HospitalType 1 Primary Hyperoxaluria

Start: 2024-07-15End: 2026-12-31Target: 21Updated: 2025-05-16

Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)

Active, not recruitingNCT06892301

Guangzhou Women and Children's Medical CenterType 1 Primary Hyperoxaluria

Start: 2025-02-27End: 2026-07-31Target: 2Updated: 2025-03-24

Phase 1

Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1)

RecruitingNCT07776626

YolTech Therapeutics Co., LtdPH1, Primary Hyperoxaluria Type 1

Start: 2026-08-01End: 2028-01-01Target: 9Updated: 2026-08-20

Phase 2

Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)

RecruitingNCT07587021

YolTech Therapeutics Co., LtdPH1, Primary Hyperoxaluria Type 1

Start: 2026-09-01End: 2028-02-01Target: 36Updated: 2026-09-08